jetcityimage / iStockphoto.com
17 October 2017Americas
AIPPI 2017: Eli Lilly counsel discusses ‘convoluted’ Amgen v Sanofi ruling
A patent counsel at Eli Lilly discussed a recent dispute pitting Amgen against Sanofi and Regeneron, saying an appeals court ruling was convoluted.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Americas
6 October 2017 The US Court of Appeals for the Federal Circuit has vacated a permanent injunction awarded to Amgen in its dispute with Sanofi and Regeneron.
Americas
6 January 2017 Sanofi and Regeneron Pharmaceuticals must stop selling cholesterol-lowering medicine Praluent after Amgen obtained an injunction against the companies.
Editor's picks
Editor's picks
Americas
6 October 2017 The US Court of Appeals for the Federal Circuit has vacated a permanent injunction awarded to Amgen in its dispute with Sanofi and Regeneron.
Americas
6 January 2017 Sanofi and Regeneron Pharmaceuticals must stop selling cholesterol-lowering medicine Praluent after Amgen obtained an injunction against the companies.
Americas
6 October 2017 The US Court of Appeals for the Federal Circuit has vacated a permanent injunction awarded to Amgen in its dispute with Sanofi and Regeneron.
Americas
6 January 2017 Sanofi and Regeneron Pharmaceuticals must stop selling cholesterol-lowering medicine Praluent after Amgen obtained an injunction against the companies.